Patient information for drug utilization review; contact information for electronically transmitted prescription, 8.21, 21.6(1)“d,” 21.7(3)
Adopted and Filed
Rule making related to patient information
The Board of Pharmacy hereby amends Chapter 8, "Universal Practice Standards," and Chapter 21, "Electronic Data and Automated Systems in Pharmacy Practice," Iowa Administrative Code.
Legal Authority for Rule Making
This rule making is adopted under the authority provided in Iowa Code section 147.76.
State or Federal Law Implemented
This rule making implements, in whole or in part, Iowa Code sections 147.76 and 155A.35.
Purpose and Summary
This rule making clarifies that patient information which is needed for a pharmacist to conduct drug utilization review shall be obtained and that the collection of such information can be delegated to a pharmacy technician or pharmacist-intern. This rule making also provides that an electronically transmitted prescription must include the telephone number where the prescriber can be contacted and updates a reference.
Public Comment and Changes to Rule Making
Notice of Intended Action for this rule making was published in the Iowa Administrative Bulletin on July 29, 2020, as ARC 5115C. The Board received one comment from the Iowa Pharmacy Association in support of the amendments. No changes from the Notice have been made.
Adoption of Rule Making
This rule making was adopted by the Board on November 17, 2020.
This rule making has no fiscal impact to the State of Iowa.
After analysis and review of this rule making, no impact on jobs has been found.
Any person who believes that the application of the discretionary provisions of this rule making would result in hardship or injustice to that person may petition the Board for a waiver of the discretionary provisions, if any, pursuant to 657—Chapter 34.
Review by Administrative Rules Review Committee
The Administrative Rules Review Committee, a bipartisan legislative committee which oversees rule making by executive branch agencies, may, on its own motion or on written request by any individual or group, review this rule making at its regular monthly meeting or at a special meeting. The Committee's meetings are open to the public, and interested persons may be heard as provided in Iowa Code section 17A.8(6).
This rule making will become effective on February 3, 2021.
The following rule-making actions are adopted:
Item 1. Amend rule 657—8.21(155A) as follows:
657—8.21(155A) Prospective drug use review.
8.21(1) For purposes of promoting therapeutic appropriateness and ensuring rational drug therapy, a pharmacist shall review the patient record, information obtained from the patient, and each prescription drug or medication order to identify:
a. to h. No change.
Upon recognizing any of the above, the pharmacist shall take appropriate steps to avoid or resolve the problem and shall, if necessary, include consultation with the prescriber. Information that shall be obtained for the purpose of drug utilization review includes, but is not limited to, a complete list of prescription and nonprescription medications being used by the patient, patient allergies, and patient disease states. The collection of patient information to be used for drug utilization review may be delegated to a pharmacy technician or pharmacist-intern. The review and assessment of patient records shall not be delegated to pharmacy technicians or pharmacy support persons but may be delegated to registered pharmacist-interns under the direct supervision of the pharmacist.
8.21(2) No change.
Item 2. Amend paragraph 21.6(1)"d" as follows:
d. In addition to the information requirements for a prescription, an electronically transmitted prescription shall identify the transmitter's telephone number for verbal confirmation, the telephone number where the prescriber can be contacted for timely consultation about patient care matters, the time and date of transmission, and the pharmacy intended to receive the transmission as well as any other information required by federal or state laws, rules, or regulations.
Item 3. Amend subrule 21.7(3) as follows:
21.7(3) Schedule II controlled substances—long-term care facility patients. A prescription for any Schedule II controlled substance for a resident of a long-term care facility, as "long-term care facility" is defined in rule 657—23.1(155A) 657—23.2(155A), may be transmitted by the prescriber or the prescriber's agent to a pharmacy via facsimile. The prescription shall identify that the patient is a resident of a long-term care facility.
[Filed 11/30/20, effective 2/3/21]
Editor's Note: For replacement pages for IAC, see IAC Supplement 12/30/20.